It has been revealed that the UFC has been notified of a failed drug test from Cris Cyborg.
In the last 2 months Cyborg was twice offered a title shot to which she replied she needed time to recover from the grueling weight cut. Cyborg famously struggled making weight for the last couple of bouts. The fight against Holm that was offered to her also had different terms, according to some reposrts Holm would agree to 138 but not to 145.
The UFC released a statement on their website:
“The UFC organization was formally notified today that the U.S. Anti-Doping Agency (USADA) has informed Cristiane “Cyborg” Justino of a potential Anti-Doping Policy violation stemming from an out-of-competition sample collection on December 5, 2016.
USADA, the independent administrator of the UFC Anti-Doping Policy, will handle the results management and appropriate adjudication of this case. It is important to note that, under the UFC Anti-Doping Policy, there is a full fair legal review process that is afforded to all athletes before any sanctions are imposed.
Consistent with all previous potential anti-doping violations, additional information or UFC statements will be provided at the appropriate time as the process moves forward.”
Cyborg made a statement Thursday and said that “recent sample contained a banned substance known as Spironolactone,” a diuretic which she said was “part of a therapeutic treatment.”
“I was given a medical suspension by [the doctor] not to enter into competition style training or weight cutting practices during the period of recovery,” Justino said in her statement. “It is for those reasons why I declined the UFC fight Feb. 11th 2016 for the first 145lbs belt.
I have been notified today by USADA of a potential violation stemming from an Out of Competition Sample collected Dec. 5 2016.
USADA is an independent administrator of the UFC Anti Doping policy and will be responsible for the review and any sanctioning if imposed.
It has been brought to my attention that my recent sample contained a banned substance known as Spironolactone. The substance is part of a therapeutic treatment being administered to me by doctor that started the 26th of September and is suppose to last for a period of no less than 90 days, requiring blood exams at the completion. In addition to the treatment administered to me by Dr Ulyssea M Da C O Pinto (CRM-PR19062/CRM-RJ 30150-9/CRM SC 2740/ CRM -RO 2630) I was given a medical suspension by her not to enter into competition style training or weight cutting practices during the period of recovery. It is for those reasons why I declined the UFC fight Feb. 11th 2016 for the first 145lbs belt.
I am proud to be a member of USADA, and was the first fighter to complete 1 year of testing under USADA programs before competing in UFC competition.
I have been tested 14 times since entering the program, twice in Q4 in 2016 and have never had a flagged sample.
My Dr. is experienced with USADA testing and informed me there were no additional steps needed for approval with the associated treatments given to me following my UFC Brasilia fight.
we are being fully cooperating with USADA at this time and have already started the process of applying for a retroactive therapeutic use exemption.
For my fans who are disappointed in the news, I am sorry.
You can feel confident that the substance they are inquiring about is not for performance enhancing use, and is needed for my specific treatments. (International Medical Codes CID E 87.6, CID 87.8, CID E 44.0, CID N 83.2, CID 115.9, CID Z73.3 CID E 06.3) Feel confident that I am a clean athlete.
It is my hope that my experiences will continue to bring awareness to the dangers of extreme weight cutting. I cut weight 3 times in 8 months during 2016 competing twice at 140lbs. It is because of the measures needed to make the required 140lbs weight limit Sept 24 that my body is needing the on-going medical treatment.
I am glad the UFC has created the 145lbs division and look forward to fighting for the belt once my body is recovered and ready to compete. Additional information or statements will be provided at the appropriate time as the process moves forward.